Englander Institute for Precision Medicine

Publications

Found 805 results
Author Title Type [ Year(Asc)]
2025
Guevara D, Shin N, Boiko A, Valiev I, Elsaeed AG, Mosquera JMiguel, Assaad MAl, Manohar J, Sigouros M, Zaichikova A et al..  2025.  Mesonephric Adenocarcinoma in a Young Male Patient.. Anticancer Res. 45(2):619-623.
Tyrakis PA, Kampjut D, Steele GF, H Lindström JG, Chirnomas D, Hopkins BD, Goncalves MD, Mukherjee S, Cantley LC, Maddocks ODK.  2025.  Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models.. Br J Cancer.
Fiore D, Cappelli LVincenzo, Zhaoqi L, Kotlov N, Sorokina M, Phillip J, Zumbo P, Yoffe L, Ghione P, Wang A et al..  2025.  A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.. Cell Rep Med. :102029.
Horne CR, Dite TA, Young SN, Mather LJ, Dagley LF, Johnson JL, Yaron-Barir TM, Huntsman EM, Daly LA, Byrne DP et al..  2025.  "PSKH1 kinase activity is differentially modulated via allosteric binding of Ca²⁺ sensor proteins". Proc Natl Acad Sci U S A. 122(8):e2420961122.
Laurent P-A, Andre F, Bobard A, Deandreis D, Demaria S, Depil S, Eichmüller SB, Fernandez-Palomo C, Foijer F, Galluzzi L et al..  2025.  Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference.. Oncoimmunology. 14(1):2432726.
Chukwu W, Lee S, Crane A, Zhang S, Webster S, Dakhama O, Mittra I, Rauert C, Imielinski M, Beroukhim R et al..  2025.  A sequence context-based approach for classifying tumor structural variants without paired normal samples.. Cell Rep Methods. :100991.
Kim J, Ravichandran H, Yoffe L, Bhinder B, Finos K, Singh A, Pua BB, Bates S, Huang BEmma, Rendeiro AF et al..  2025.  Simultaneous immunomodulation and epithelial-to-mesenchymal transition drives lung adenocarcinoma progression.. bioRxiv.
Lv W, Zeng Y, Li C, Liang Y, Tao H, Zhu Y, Sui X, Li Y, Jiang S, Gao Q et al..  2025.  Spatial-Temporal Diversity of Extrachromosomal DNA Shapes Urothelial Carcinoma Evolution and the Tumor Immune Microenvironment.. Cancer Discov. :OF1-OF22.
Rubinelli L, Manzo OLaura, Sungho J, Del Gaudio I, Bareja R, Marino A, Palikhe S, Di Mauro V, Bucci M, Falcone DJ et al..  2025.  Suppression of endothelial ceramide de novo biosynthesis by Nogo-B contributes to cardiometabolic diseases.. Nat Commun. 16(1):1968.
Yost KE, Zhao Y, Hung KL, Zhu K, Xu D, M Corces R, Shams S, Louie BH, Sarmashghi S, Sundaram L et al..  2025.  Three-dimensional genome landscape of primary human cancers.. Nat Genet. 57(5):1189-1200.
Breves SL, Di Giammartino DCampigli, Nicholson J, Cirigliano S, Mahmood SRaza, Lee UJin, Martinez-Fundichely A, Jungverdorben J, Singhania R, Rajkumar S et al..  2025.  Three-dimensional regulatory hubs support oncogenic programs in glioblastoma.. Mol Cell.
Guevara D, Shin N, Boiko A, Valiev I, Elsaeed AG, Mosquera JMiguel, Assaad MAl, Manohar J, Sigouros M, Zaichikova A et al..  2025.  Unusual Presentation of Advanced Urothelial Cancer in a Young Patient.. Anticancer Res. 45(2):613-618.
Bonacci RE, McGill M, Le NThuy Anh, Barkarar M, Finnegan C, Wilson M, Ajagbe O, Udekwu CC, Gorski K, Manohar J et al..  2025.  Upregulation of the interferon-inducible antiviral gene RSAD2 in neuroendocrine prostate cancer via PVT1 exon 9 dependent and independent pathways.. J Biol Chem. :108370.
2024
Guillet S, Lazarov T, Jordan N, Boisson B, Tello M, Craddock B, Zhou T, Nishi C, Bareja R, Yang H et al..  2024.  ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosis.. Elife. 13
Lira MCecilia, Vanpouille-Box C, Galluzzi L.  2024.  Adaptive inhibition of CGAS signaling by TREX1.. Trends Cancer. 10(3):177-179.
San Pedro JManuel Bra, Aranda F, Buqué A, Galluzzi L.  2024.  Animal models of disease: Achievements and challenges.. Methods Cell Biol. 188:xv-xxi.
Stenzl A, Armstrong AJ, Sboner A, Ghith J, Serfass L, Bland CS, Schijvenaars BJA, Sternberg CN.  2024.  Artificial INtelligence to Support Informed DEcision-making (INSIDE) for Improved Literature Analysis in Oncology.. Eur Urol Focus.
Desai P, Zhou Y, Grenet J, Handelman SK, Crispino CM, Tarbay LN, Whitsel EA, Roboz G, Barac A, Honigberg M et al..  2024.  Association of clonal hematopoiesis and mosaic chromosomal alterations with solid malignancy incidence and mortality.. Cancer.
De Martino M, Rathmell JC, Galluzzi L, Vanpouille-Box C.  2024.  Author Correction: Cancer cell metabolism and antitumour immunity.. Nat Rev Immunol.
Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P et al..  2024.  Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.. Nat Commun. 15(1):225.
Rajendran S, Brendel M, Barnes J, Zhan Q, Malmsten JE, Zisimopoulos P, Sigaras A, Ofori-Atta K, Meseguer M, Miller KA et al..  2024.  Automatic ploidy prediction and quality assessment of human blastocysts using time-lapse imaging.. Nat Commun. 15(1):7756.
Sridhar SS, Powles T, Durán MÁCliment, Park SHoon, Massari F, Thiery-Vuillemin A, Valderrama BP, Ullén A, Tsuchiya N, Aragon-Ching JB et al..  2024.  Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.. Eur Urol. 85(2):154-163.
Shah Y, Kulm S, Nauseef JT, Chen Z, Elemento O, Kensler KH, Sharaf RN.  2024.  Benchmarking multi-ancestry prostate cancer polygenic risk scores in a real-world cohort.. PLoS Comput Biol. 20(4):e1011990.
Meleshko D, Yang R, Maharjan S, Danko DC, Korobeynikov A, Hajirasouliha I.  2024.  Blackbird: structural variant detection using synthetic and low-coverage long-reads.. bioRxiv.
De Martino M, Rathmell JC, Galluzzi L, Vanpouille-Box C.  2024.  Cancer cell metabolism and antitumour immunity.. Nat Rev Immunol.